Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Resources / EDRN Standard Operating Procedures (SOP) / Assays / Immunohistochemistry / Immunoperoxidase Protocol for Dako Autostainer

Immunoperoxidase Protocol for Dako Autostainer

  1. Cut tissue sections at 3-5 microns and mount on appropriate control box slides.
  2. Bake slides for 30 minutes in 70°C - 90°C oven.
  3. Label slides with necessary information including antibody.
  4. Deparaffinize slides in 3 changes of xylene 5 minutes each.
  5. Bring slides through 2 changes of absolute alcohol and 1 change of 95% alcohol 2 minutes each.
  6. Rinse in 2 changes of distilled waters. Then place in buffer solution.
  7. Perform any digestion or antigen retrieval protocols now if necessary.
  8. Set up DAKO autostainer with all reagents and antibodies necessary.
  9. Load slides and start machine.
  10. When completed, remove slides and wash in running tap water 2-5 minutes.
  11. Dehydrate slides

    Rinse 15-20 dips in

    • 2 changes 95% ETOH
    • 2 changes ABS ETOH
    • 3 changes Xylene
  12. Coverslip on automatic coverslipper.
New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.